Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Atlas Copco has acquired a German distributor of industrial compressors and service

Atlas Copco has acquired Dr. Gustav Gail Drucklufttechnik GmbH.  The company is located in the southern part of Cologne and has a strong market presence in same area.Dr. Gustav Gail Drucklufttechnik GmbH has 10 employees. “The company has a strong presence and potential for growth in the area in and around Cologne,” said Vagner Rego, Business Area President Compressor Technique. “The acquisition is in line with our strategy to increase our service offering and get closer to our customers”.   The purchase price is not material relative to Atlas Copco’s market capitalization and is

YEAR END REPORT

Peptonic Medical AB (publ) org nr 556776-3064 (www.spotlightstockmarket.com ,  ticker: PMED) Period from January to December 2019 2019 FOURTH QUARTER (Oct-Dec) · Net sales of products KSEK 394 (263) · Gross profit KSEK 321 (137), Gross margin 81% (52%) · Operating loss KSEK -11,508 ( -4,642)  · Loss per share SEK -0.09 (-0.06) FULL YEAR 2019 (Jan-Dec) · Net sales of products KSEK 4,408 (383) · Gross profit KSEK 2,583 (232), Gross margin 59% (61%) · Operating loss KSEK 23,922 (-14,311) · Loss per share SEK -0.18 (-0.17)From the CEO We can now look

Year-end report 2019, Interim Report 4, 2019 - Continued profitable growth, new financial targets and new segment

Speqta AB (plc) year-end report and interim report for the period October 1 – December 31 2019, is published and available on https://speqta.com/en/investors/financial-reports Significant events during fourth quarter · Revenues during fourth quarter increased by 32% to KSEK 27,463 (20,757). · EBITDA increased by 16% to KSEK 4,136 (3,567) and EBITDA-margin was 15% (17). · Adjusted EBITDA increased by 5% to KSEK 4,136 (3,945), corresponding to a margin of 15% (19). · Earnings per share SEK -0.01 (0.02) · Segment Shopping sales increased by 40% and to KSEK 24,086 (17,

Mentice publishes the company’s year-end report for the period January–December 2019

Encouraging signs for 2020, despite continued lag in the medical device industry in Q4 Fourth quarter 2019 · Net sales amounted to 60.2 (65.2) MSEK. · Operating result for the period before depreciations (EBITDA) totaled  11.8 (24.3) MSEK. · Net result for the period amounted to 7.8 (27.8) MSEK. · Earnings per share (EPS) was 0.32 (2.48) SEK. · Order intake amounted to 54.7 (61.9) MSEK. · The order book was 39.8 (50.1) MSEK. · Cash flow from operating activities totalled -17.4 (12.4) MSEK. January-December 2019 · Net sales amounted to 149.4 (157.0) MSEK.

Year-End report January - December 2019

Fourth quarter in brief · SyntheticMR had a sales growth of -31% in the fourth quarter compared to the previous year. · Net sales amounted to 10.6 MSEK (15.3). · Operating profit amounted to -4.6 MSEK (5.4), of which -2.2 MSEK relates to SyntheticMR U.S. Inc. · Profit for the period amounted to -3.5 MSEK (4.4). · Earnings per share amounted to -0.84 SEK (1.10).   Full year in brief · Net sales amounted to 45.8 MSEK (48.3), which means a sales growth of -5%. · Operating profit amounted to 4.9 MSEK (18.7), of which -2.7 MSEK relates to SyntheticMR U.S. Inc. ·

Norwegian Energy Company ASA – Buyback of own shares

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN OR INTO THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR OTHER MEASURES. Oslo, 27 February 2020: Reference is made to the stock exchange release of 20 January 2020 in which Norwegian Energy Company ASA (“Noreco” or the “Company”) initiated a share buyback of up to 360,000 own shares and the subsequent resolution to buy back 299,925 own shares. Subsequent to this, Noreco has decided to initiate a new

Wallenstam invests in solar cells

Wallenstam was the first in the sector to be self-sufficient in renewable energy with its investment in wind power. Now the company is taking the next step in its sustainability work by complementing this with solar cells. The entire property holdings comprising around 220 properties have been analyzed to evaluate the potential for installation of solar cells.“As you know, we were the first in the sector to be self-sufficient in renewable energy as far back as 2013 through our wind turbines. To complement this with solar cells is an important step in our sustainability work and supports one

Complete proposals to the Extraordinary General Meeting of Alzinova later today, 27 February 2020

On 13 February 2020, Alzinova AB (“Alzinova”) convened an Extraordinary General Meeting for later today, 27 February 2020. The Company can now present the finalized proposals regarding the number of board members of the Company and the appointment of a new board member.The proposals suggest that the Board of Directors shall comprise five members up until the end of the next Annual General Meeting. It is further proposed that Pernilla Sandwall is elected as new member of the board for the period up until the end of the next Annual General Meeting. Pernilla has 30 years of experience from

Notice of Annual General Meeting in Fabege AB (publ)

Shareholders of Fabege AB (publ) are hereby notified of the Annual General Meeting (AGM) to be held on Thursday, 2 April 2020, at 3:00 pm at Filmstaden Scandinavia, Westfield Mall of Scandinavia, Råsta Strandväg 19A Solna, Sweden. Registration for the AGM begins at 2.15 pm.Notice of Participation Shareholders who wish to participate in the AGM must be registered as shareholders in the share register maintained by Euroclear Sweden AB (formerly VPC AB) on Friday, 27 March 2020, and must also notify Fabege of their intention to participate and the participation of any accompanying advisors

Interim report October - December 2019

The full Interim report is available on Brighter's website https://brighter.se. The Interim report is also attached as a pdf file to this press release. October - December 2019. · Capitalized expenditure for development work reached SEK 9,729 thousand (11,075). · Net sales reached SEK 2,398 thousand (0). · Operating result amounted to SEK -35,029 thousand (-10,843). · Earnings before tax amounted to SEK -34,527 thousand (-13,141). · Earnings per share, before dilution amounted to SEK -0.30 (-0.17). Difference in operating result refers among other things to a write-

Notice of the Annual General Meeting of Cloetta AB (publ)

Shareholders of Cloetta AB (publ), 556308-8144, are hereby invited to attend the Annual General Meeting, to be held on Thursday, 2 April 2020 at 3:00 p.m. at Stockholm Waterfront Congress Centre, Nils Ericsons Plan 4 in Stockholm, Sweden.Notification of attendanceShareholders who wish to attend the Annual General Meeting must, firstly, be listed in the shareholders' register maintained by Euroclear Sweden AB (the Swedish Central Securities Depository), on Friday, 27 March 2020, and secondly, give notice to the company of their intention to attend the meeting no later than Friday, 27 March

Össur hf: Final agenda and proposals for the Annual General Meeting 12 March 2020

Announcement no. 16/2020 27 February 2020    Final agenda and proposals Enclosed is the final agenda and proposals for Össur's Annual General Meeting to be held on Thursday 12 March 2020. The meeting will be held at Össur's headquarters at Grjótháls 5, Reykjavik, Iceland. No changes have been made to the previously announced agenda and proposals. Further information David Hreidarsson, Investor Relations, dohreidarsson@ossur.com, +354 515 1380 Helga Danielsdottir, Investor Relations, hdanielsdottir@ossur.com, +354 515 1380 Össur press releases by e-mail If you

Director/PDMR Shareholding

27 February 2020 07:00 GMT     TRANSACTION BY PERSON DISCHARGING MANAGERIAL RESPONSIBILITIES Disclosure under Article 19 of the EU Market Abuse Regulation   AstraZeneca PLC (the Company) announces that, on 26 February 2020, it was notified by Tony Mok, a Non-Executive Director of the Company, that, on 26 February 2020, Mr Mok purchased 1,000 of the Company's American Depositary Shares (ADSs) at a price of $48.00 per ADS. Two ADSs are equivalent to one Ordinary Share of $0.25 in the Company. The attached notification, made in accordance with the requirements of the EU

Arjo initiates a randomized controlled trial for wound care treatment after strong evaluation results

Arjo will today publish the results from a highly successful multi-centre clinical evaluation for the recently launched WoundExpress™. WoundExpress is a ground breaking patented therapy for Venous Leg Ulcers (VLU). Further clinical research studies, including a pivotal randomised controlled trial, are now underway. Arjo aims to establish WoundExpress as the standard of care, given the clear improvements in outcomes for patients and the healthcare system alike. Venous leg ulcers are a rapidly growing problem worldwide with high ongoing treatment costs amounting to over SEK 100 billion, as

New Major Shareholders in Toadman (Soon to Be EG7) in Dan Sten Olsson With Family, Takes Board Position

Dan Sten Olsson with family now hold approximately 2.1 million shares in the company and are proposed to be represented in the board by Erik Nielsen. The Stena Olsson family together with Erik Nielsen has acquired an additional 1.6 million shares in Toadman Interactive AB (under name change to EG7). In total, the group of investors now owns approximately 2.1 million shares in the company worth approximately SEK 57m and is therefore collectively the fifth largest shareholder. In connection with this, Toadman’s shareholder, who represent more than 50% of the ownership, presents a

Year-end report January-December 2019

· Profit from property management attributable to parent company shareholders amounted to SEK 4,023m (3,304), corresponding to an increase per share by 22 % to SEK 22.35 (18.35) · Long term net asset value amounted to SEK 345.76 per share (280.17) · Rental income amounted to SEK 7,609m (6,714) · Profit after tax attributable to parent company shareholders amounted to SEK 8,958m (9,308) corresponding to SEK 49.77 per share (51.71)  Profit from property management for the year amounted to SEK 4,604m (3,877). Profit from property management attributable to parent company

Sedana Medical donates AnaConDa to hospitals in Wuhan, China

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company is donating the medical device AnaConDa and accessories for anti-epidemic use and evaluation of the effects of inhalation sedation with AnaConDa on severely ill Corona virus affected patients to two hospitals in Wuhan and Zhejiang, China.Sedana Medical is a pioneer in making volatile anaesthetics available to critically ill mechanically ventilated patients via the medical device AnaConDa. In the current situation, with the outbreak of the novel coronavirus (2019-nCoV), Sedana Medical wants to contribute by

Year-End Report 2019

1 January 2019 - 31 December 2019 (12 months)FOURTH QUARTER OCTOBER - DECEMBER 2019Revenues:0 KSEK (0). Operating earnings after taxes -1 888 KSEK (-2 947).Net income per share:-0,21 SEK (-0,12). JANUARY - DECEMBER 2019Revenues:0 KSEK (0). Operating earnings after taxes -7 679 KSEK (-9 781).Net income per share:-0,87 SEK (-0,42). Solidity: 75% (78). Net income per share: Net income for the period divided by the average number of shares during the period. Total number of share * as of 30 December 2019 amounted to 8 872 315 shares.IMPORTANT EVENTS DURING 2019 · On 28

Year-end report for BEWiSynbra Group for the period January to December 2019

HIGHLIGHTS for 2019 Numbers in parentheses refers to the corresponding periods in the previous year Fourth quarter · BEWiSynbra Group reported net sales of SEK 1,108.8 million for the fourth quarter (SEK 1,219.5 million), a decrease of 9.0 per cent compared to the corresponding quarter last year · Adjusted EBITDA was SEK 101.6 million (SEK 100.6 million), while adjusted EBITA amounted to SEK 44.1 million (SEK 62.5 million) · Earnings were negatively impacted by items affecting comparability of SEK 9.6 million for the quarter (negatively impacted by SEK 19.5 million) ·

Relais Group Plc Financial Statement Bulletin 1 January – 31 December 2019 (unaudited) – Powerful growth through acquisitions

Relais Group Plc Company Release 27 February 2020 at 9.00 a.m.Relais Group Plc Financial Statement Bulletin 1 January – 31 December 2019 (unaudited) – Powerful growth through acquisitions This release is a summary of Relais Group’s Financial Statement Bulletin 2019. The full release is attached to this company release and is available on our website at https://relais.fi/en/investors/. Relais Group Plc acquired the shares of AB Reservdelar (ABR) and Huzells i Karlstad AB on 31 May 2019. The companies have been included in Relais Group’s consolidated balance sheet from 31 May 2019

Year-End Report

with quarterly report for the period 1 October 2019 to 31 December 2019 Full year 2019 in summary · Net sales amounted to 151,645 kSEK · Adjusted EBITDA amounted to 22,960 kSEK excluding non-recurring items of 19,862 kSEK · EBITDA amounted to 3,098 kSEK · Cash balance amounted to 105,740 kSEK · Net debt amounted to 126,372 kSEK · Equity amounted to 250,126 kSEK · Earnings per share amounted to -0,0009 SEK Fourth quarter in summary · Sales amounted to 56,740 (66,460) kSEK · Adjusted EBITDA amounted to 4,613 kSEK, excluding non-recurring items of 22,000

Polygiene AB (publ.) Interim Report October 1–December 31 2019

Growth, continuous strong gross margin and improved cashflow compared to last year.Q4 in brief · Net sales increased by 2.1 % during the fourth quarter compared to the same period last year and amounted to MSEK 19.0 (18.6). Adjusted from the divestment of Protective surfaces, the corresponding figure is 6.7 %. · The operating profit/loss before tax for the period ended at MSEK -2.2 (0.5). The result is affected by MSEK 1.2 in extraordinary costs. · The gross margin is continuous strong and amounted to 68.6 (63.3) % for the period. · Cash flow of the fourth quarter improved

ContextVision Grows Medical Imaging Market Footprint With New Global Customers

STOCKHOLM – February 27, 2020 – ContextVision, a medical technology software company specializing in image analysis and artificial intelligence, announced new growth within its market-leading medical image processing business. Newly signed customer contracts in both Asia and the United States are driving increased revenue in Q1 2020 and beyond. ContextVision continues to set the highest global industry standards across various imaging modalities. The company’s important value proposition for its image enhancement products and services is further validated by these new contracts and

Redeye: Gaming Innovation Group - All-in on B2B

Redeye cuts the valuation of GiG as a consequence of its B2C divestment. While the Q4’19 report otherwise was uneventful, the strategic move is significant. On a positive note, financial gearing is coming down and the remaining B2B business is developing well. We view the selling price as clearly low, however, and the future potential is reduced due to this effective halving of GiG’s business. On balance, we still see substantial upside in the stock from currently depressed levels. Read more and download the research update: http://bit.ly/GIG-B2B Start following companies at Redeye to

There are no items matching the current filter
There are no more items matching the current filter
Back to top